Cladribine tablets (Mavenclad) have been listed on the Pharmaceutical Benefits Scheme (PBS) from 1 January 2019 for relapsing remitting MS (RRMS). The listing follows a recommendation by the Pharmaceutical Benefits Advisory Committee, which concluded in July 2018 had acceptable cost effectiveness in MS when compared to fingolimod. Cladribine is an immunosuppressive agent that targets lymphocytes ...
Already a member?
Enter your email to keep reading.